On February 3, 2026, a federal jury in the Northern District of Georgia returned a complete defense verdict for Teva Pharmaceuticals in Rickard v. Teva Pharmaceuticals USA Inc. et al., the first bellwether trial in MDL 2974. The jury rejected all six liability theories after approximately four hours of deliberation. The formal judgment, entered February 4, ordered that "plaintiff take nothing" and dismissed the action.
The verdict landed in a docket with more than 3,800 pending federal cases, raising immediate questions about the bellwether process and the viability of failure-to-warn theories across the remaining inventory. Coverage of the verdict drew procedural parallels to other mass-tort dockets currently testing manufacturer liability theories.
This article covers JPML centralization, the corporate ownership chain, bellwether trial mechanics, dispositive rulings on preemption and limitations, and practice implications.
How MDL 2974 Was Formed and What Allegations Drive the Litigation
The Judicial Panel on Multidistrict Litigation centralized the Paragard IUD litigation on December 16, 2020, in In re Paragard IUD Prods. Liab. Litig., 510 F.Supp.3d 1376 (J.P.M.L. 2020). The order consolidated 55 federal actions pending in 31 districts into the Northern District of Georgia.
The Panel selected the N.D. Ga. because no single forum dominated the caseload; six constituent actions were already filed there. Defendants opposed centralization, but the Panel found common questions of fact predominated. Judge Leigh Martin May received the assignment and has presided over the docket since.
The core allegations center on the Paragard T380A intrauterine copper contraceptive (NDA 018680), FDA-approved in 1984. Plaintiffs allege the device's polyethylene arms fracture during removal rather than folding upward as described in the 2013 label. Specific injury categories include:
- Arm fracture during removal, with retained fragments embedding in the myometrium or migrating to the peritoneal cavity
- Surgical retrieval procedures (hysteroscopy, laparoscopy, hysterectomy) and resulting fertility complications
- Inadequate labeling that failed to warn of the distinct fracture risk
As of January 2026, the JPML statistics report recorded 3,800 actions pending and 4,071 total actions filed.
What the Paragard Corporate Ownership Chain Means for Defendant Liability
The Paragard NDA ownership history has included Population Council/GynoPharma, FEI Women's Health, Duramed/Barr, Teva, and CooperSurgical, and that timeline controls which defendant faces exposure for which claims. Early transfer details are limited in the public record, but the later transitions relevant to the bellwether cases are documented:
- Population Council/GynoPharma: original 1984 NDA approval era
- Duramed Pharmaceuticals (Barr subsidiary): acquired FEI Women's Health and the NDA-related business in November 2005
- Teva Pharmaceuticals: absorbed Barr in December 2008, with Paragard later held within Teva's women's health entities
- CooperSurgical: purchased Paragard's assets and global rights for $1.1 billion, November 2017
All three bellwether plaintiffs received their devices during the Teva era: Robere in June 2011, Rickard in May 2012, Braxton in 2013. Each device was removed after CooperSurgical acquired the NDA in November 2017. This temporal split became dispositive.
On November 21, 2025, Judge May granted CooperSurgical summary judgment on design defect claims. Cooper was not the NDA holder when the devices were placed and could not have modified a design unchanged since 1984. The court deferred ruling on Cooper's failure-to-warn exposure pending supplemental causation briefing on whether Cooper's control of the label between November 2017 and the bellwether plaintiffs' failed removals supported liability.
How the Bellwether Pool Was Selected and Tried
The bellwether framework, established by CMO Doc. 431 in February 2023 and refined by the Fourth Amended CMO (Doc. 870) entered February 11, 2025, required a substantially complete Plaintiff Fact Sheet dated on or before December 1, 2022, with no pending deficiencies. The framework used party picks, court random selections, and alternating strikes to narrow a 10-case pool to three trial cases.
The three trial cases that emerged:
- Rickard (1:21-cv-03861), defense selection
- Robere (1:22-cv-00490), court random selection
- Braxton (1:22-cv-01583), court random selection
On September 24, 2025, the court reordered the trial sequence to Rickard first, then Robere, then Braxton, per a party agreement. On January 12, 2026, Judge May denied Teva's motion to delay the Rickard trial for interlocutory appeal, finding Teva failed to raise a controlling question of law.
What the Rickard Defense Verdict Means for the MDL Going Forward
Rickard was tried over two weeks, January 20 through February 3, 2026, before Judge May. Pauline Rickard received her Paragard in May 2012 and filed suit in 2021 after the device fractured during removal. Rickard's claims against CooperSurgical were dismissed before trial, leaving Teva as the sole trial defendant.
The jury rejected all six liability theories submitted:
- Strict liability failure to warn
- Negligent failure to warn
- Strict liability defective design
- Negligent design
- Negligent misrepresentation
- Fraudulent omission
Because the jury found no liability on any theory, it did not reach the damages questions on the verdict form, which would have addressed past pain and suffering, mental anguish, medical expenses, and punitive damages contingent on a finding of intentional harm.
At the February 17, 2026 status conference, the court rescheduled Robere to Fall 2026 (originally set for March 3) and deferred Braxton (originally May 11), permitted Teva to file renewed interlocutory appeal motions in Robere and Braxton, and instructed counsel to confer on additional bellwether trials and case-specific discovery. Judge May also questioned the bellwether process as a mechanism to resolve the full inventory.
Federal Preemption, Statute of Limitations, and Choice-of-Law Posture
Three rulings entered between February 2025 and December 2025 define the legal architecture for the remaining inventory. Each addresses a distinct procedural barrier that will shape case viability across the 3,800-case docket.
December 2025 preemption ruling. Judge May rejected Teva's impossibility preemption defense on failure-to-warn claims, applying Wyeth v. Levine, 555 U.S. 555 (2009).
The court held that a manufacturer cannot invoke impossibility preemption when its own noncompliance, including miscoded adverse event reports and an overdue FDA safety review, created the information gap. The ruling preserved the central failure-to-warn theory for trial.
On design defect, the ruling split: two design theories survived (use of Dupont 2005 rather than Dupont 20 for the base material, and barium sulfate content), while two were preempted as major changes requiring prior FDA approval.
February 2025 statute of limitations order (Doc. 868). Judge May applied state-specific accrual standards under the June 2024 choice-of-law ruling, applying accrual at injury rather than subjective discovery in the dismissed jurisdictions.
Cases originating in Alabama, Idaho, Michigan, Mississippi, New York, and Virginia were dismissed as time-barred, a pattern consistent with how mass tort dockets treat jurisdiction-specific accrual rules. Cases in states applying discovery-based accrual rules survived, narrowing the inventory before the bellwether selection round.
June 2024 choice of law (Doc. 675). Each case proceeds under the substantive law of its originating state, consistent with Van Dusen v. Barrack, 376 U.S. 612 (1964). Florida law governs all three bellwether plaintiffs' claims. This ruling drove both the SOL dismissals and the preemption analysis.
Practice Implications for Plaintiff and Defense Counsel
The Rickard verdict may reshape strategic calculations across the MDL. The complete rejection of all six theories signals that general causation evidence and label-inadequacy arguments alone did not carry the case to a plaintiff verdict.
For Plaintiff Counsel
At the November 2025 summary judgment hearing, defense counsel argued that prescribing physicians rarely reviewed the Paragard warning label, undermining causation under the learned intermediary doctrine. The defense verdict gives that argument added significance. Future bellwether plaintiffs must develop physician testimony showing that an updated warning would have changed clinical conduct.
Specifically, plaintiff counsel will need to depose implanting and removing physicians on their actual label-review practices and on how a stronger fracture warning would have altered counseling, technique, or device selection. Generic causation evidence and label-inadequacy arguments alone did not carry Rickard, and the same evidentiary structure is unlikely to carry Robere or Braxton without targeted physician-specific proof.
Plaintiff counsel should also prioritize device-handling discovery from implanting and removing physicians, retained-fragment imaging chronologies, and comparative breakage rate data relative to other IUD products. The 2015 Dr. Siyu Liu pharmacovigilance analysis identifying breakage as a reportable adverse event remains a foundational document for the failure-to-warn theory.
For Defense Counsel
The learned intermediary defense and FDA labeling history carried strategic weight in Rickard. The June 2024 label revision and the February 12, 2021 OPDP warning letter to CooperSurgical anchor the regulatory history. Defense teams should preserve the preemption record for Eleventh Circuit review; Teva's renewed interlocutory appeal motions in Robere and Braxton are due within 14 days of the February 17 status conference.
For Coverage Counsel
The temporal liability split creates divided coverage postures across the Teva and Cooper policy periods. Carriers underwriting either manufacturer face different exposure profiles depending on when the device was implanted and removed:
- Teva: pre-November 2017 exposure tested in Rickard (defense verdict on all theories)
- Cooper design defect: eliminated for all pre-2017 implantation cases (November 2025 SJ)
- Cooper failure-to-warn (pre-2017 implants): summary judgment briefing pending as of trial
The Rickard verdict does not test Cooper's post-acquisition conduct because Cooper was dismissed before trial. Coverage counsel evaluating Cooper-era reserves must therefore treat Rickard as an incomplete data point and continue tracking remand-eligible cases involving post-2017 implantations.
What the Paragard MDL Signals for Bellwether-Driven Mass Tort Strategy
Rickard is an inflection point. A defense-side bellwether selection went to trial and produced a complete verdict rejecting every liability theory submitted. Robere and Braxton will determine whether Rickard is an outlier or the modal outcome across the inventory.
Until those trials land, the posture is asymmetric. Teva can point to a jury verdict while plaintiffs must demonstrate that Rickard's facts were not representative of the broader docket. Judge May's willingness to reconsider the bellwether structure itself adds a procedural variable that neither side fully controls. Procedural parallels to other device dockets suggest warning adequacy and surgeon reliance will remain central to upcoming trials.
For coverage and bellwether posture in a parallel device MDL, see the hernia mesh litigation analysis.
